Novo Nordisk's CEO Has a Comeback Plan
When Maziar Mike Doustdar took over as CEO of Novo Nordisk last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with Jessica Mendoza about his plans to turn the company around, the recent success of their Wegovy pill and what keeps him up at night. Further Listening: - Ozempic Is a…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like The Journal. →
Novo Nordisk hits back at copycat drugs
Introducing The Journal: Trillion Dollar Shot
Weight boss? Competition for Novo Nordisk
Here's How the New Weight Loss Drugs Could Change Everything
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.